All In Biotech

NDA 050627 · Sanofi Aventis US

Rifadin

Rifampin · Injection

Orphan

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

May 25, 1989

Approved uses

1

Original approval plus efficacy supplements

Registered trials

627

95 Phase 3, 60 recruiting

FAERS reports

10,069

9,802 serious, 1,594 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 25, 1989 Original approval · Type 3 - New Dosage Form
1 products under this application
  • RIFADIN · RIFAMPIN 600MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Rifampin" as an intervention, any sponsor and status, largest first.

All 627 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction1,008
  • pyrexia919
  • drug reaction with eosinophilia and systemic symptoms558
  • drug ineffective518
  • vomiting452
  • drug-induced liver injury442
  • nausea394
  • acute kidney injury362
  • jaundice360
  • condition aggravated347
  • thrombocytopenia310
  • rash302

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004214
2005242
2006308
2007255
2008316
2009337
2010337
2011331
2012516
2013558
2014555
2015676
2016721
2017917
20181,082
20191,023
2020929
2021610
202233
202334
202423
202528
202620

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rifadin (Rifampin)

2024 spending

$27K

Beneficiaries

n/a

58 claims

Per beneficiary

n/a

$186.18 per unit

View as table
YearSpending
2020$49,174
2021$25,601
2022$60,830
2023$46,452
2024$26,530

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 776 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.